(Q53222425)

English

Ras inhibition in hepatocarcinoma by S-trans-trans-farnesylthiosalicyclic acid: association of its tumor preventive effect with cell proliferation, cell cycle events, and angiogenesis.

scientific article published on 31 August 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21882255

Ras inhibition in hepatocarcinoma by S-trans-trans-farnesylthiosalicyclic acid: association of its tumor preventive effect with cell proliferation, cell cycle events, and angiogenesis. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21882255

author name string

Peter Stärkel

1

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21882255

Nicolas Charette

2

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21882255

Ivan Borbath

3

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21882255

Tanja Schneider-Merck

4

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21882255

Christine De Saeger

5

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21882255

Jorge Abarca

6

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21882255

Isabelle Leclercq

7

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21882255

Yves Horsmans

8

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21882255

publication date

31 August 2011

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21882255

Molecular Carcinogenesis

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21882255

51

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21882255

10

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21882255

816-825

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21882255

Novel advancements in the management of hepatocellular carcinoma in 2008.

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Molecular classification and novel targets in hepatocellular carcinoma: recent advancements

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

The role of signaling pathways in the development and treatment of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Blocking oncogenic Ras signaling for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Dislodgment and accelerated degradation of Ras.

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid).

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Targeting of K-Ras 4B by S-trans,trans-farnesyl thiosalicylic acid

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

The Ras inhibitor farnesylthiosalicyclic acid (FTS) prevents nodule formation and development of preneoplastic foci of altered hepatocytes in rats.

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Inhibition of the Ras oncoprotein reduces proliferation of hepatocytes in vitro and in vivo in rats

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Molecular prognostication of liver cancer: end of the beginning

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Farnesyl derivatives of rigid carboxylic acids-inhibitors of ras-dependent cell growth

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Experimental models of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Application of comparative functional genomics to identify best-fit mouse models to study human cancer

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver.

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

NF-κB and STAT3 - key players in liver inflammation and cancer

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Oncogenic activation of NF-kappaB.

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

STAT3 as a central mediator of neoplastic cellular transformation

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

G protein coupled receptor signaling through the Src and Stat3 pathway: role in proliferation and transformation

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Ha-ras oncogene-induced Stat3 phosphorylation enhances oncogenicity of the cell

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Ras/ERK1/2-mediated STAT3 Ser727 phosphorylation by familial medullary thyroid carcinoma-associated RET mutants induces full activation of STAT3 and is required for c-fos promoter activation, cell mitogenicity, and transformation.

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Signal transducer and activator of transcription 3 (Stat3) in epithelial carcinogenesis

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

MSK activation and physiological roles

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

The mTOR pathway: a new target in cancer therapy.

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Identifiers

10.1002/MC.20849

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21882255

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21882255

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53222425&oldid=825188474"